Events

HubXchange w/ Bryn-Williams Jones

Join our VP of Drug Discovery, Bryn Williams-Jones, at hubXchange’s European Hybrid AI in Drug Discovery Xchange 2021

HubXchange brings together executives from pharma and biotech to address and find solutions to the key issues faced in AI-led drug discovery. In this talk, Bryn Williams-Jones, VP Drug Discovery, will explore how he bridges the world’s of science and technology to help guide technologists in their work to develop AI tools that meet hyper-specific scientific requirements. He will then demonstrate how BenevolentAI applies these tools to empower target identification and precision medicine. Bryn will cite case studies from BenevolentAI’s work in novel target discovery, drug repurposing and in collaboration with AstraZeneca.

Register here →



Bryn Williams-Jones

VP Drug Discovery at BenevolentAI

Bryn is responsible for driving the application of AI-augmented drug discovery to disease hypothesis generation across the BenevolentAI portfolio bringing together the key scientific and AI strands of research. Before joining BenevolentAI Bryn lead the Open PHACTS IMI project, and is CEO of the Open PHACTS Foundation project building open semantic web infrastructure for drug discovery. Prior to that Bryn worked at Pfizer across a wide range of Therapeutic Areas applying data and computational science to early drug discovery hypothesis generation.

More Posts

You Might Also Like

News
BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca
AstraZeneca selects another novel target for idiopathic pulmonary fibrosis from the collaboration for its drug development portfolio.
May 17, 2022
Blog
FDA converts emergency approval of baricitinib — first identified as a COVID treatment by BenevolentAI — to a full approval
The FDA has converted its emergency approval of baricitinib to a full approval, underscoring the strength of BenevolentAI’s AI-derived hypothesis.
May 12, 2022
News
Notifications of persons discharging managerial responsabilities
May 5, 2022
News
PDMR Notification (Dr. Olivier Brandicourt)
May 5, 2022
News
PDMR Notification (Jean Raby)
May 5, 2022
News
Notifications of Major Holdings
Apr 29, 2022